ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1686

Vertebral Fracture Assessment-Detected Abdominal Aortic Calcification Enhances Cardiovascular Disease Risk Stratification of Rheumatoid Arthritis Patients

Ausaf Mohammad1, Derek Lohan2, Diane Bergin2, Sarah Mooney2, John Newell3, Martin O'Donnell4, Robert J. Coughlan1 and John J. Carey1, 1Rheumatology, Galway University Hospitals, Galway, Ireland, 2Radiology, Galway University Hospitals, Galway, Ireland, 3Clinical Research Facility, National University of Ireland, Galway, Ireland, 4Clinical Research Facility, Galway University Hospitals, Galway, Ireland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, rheumatoid arthritis (RA) and risk assessment

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Rheumatoid Arthritis and Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Vertebral Fracture Assessment-detected Abdominal Aortic Calcification Enhances Cardiovascular Disease Risk Stratification of Rheumatoid Arthritis Patients

 

Background/Purpose: Osteoporosis and cardiovascular disease (CVD) are major comorbidities and CVD is the leading cause of death among patients with rheumatoid arthritis(RA). Traditional CVD risk prediction tools i.e., Framingham risk score(FRS) under-estimate the risk of CVD in RA. Novel biomarkers and better risk prediction tools are needed. Many RA patients undergo DXA today as part of an osteoporosis assessment, which may include a vertebral fracture assessment(VFA). VFA technology has been shown to reliably detect and quantify abdominal aortic calcification(AAC). VFA-detected AAC is an independent robust marker of CVD in other populations. It is unknown whether VFA-detected AAC is a useful marker of CVD in RA. We aimed to determine whether VFA-detected AAC is independently associated with CVD in RA patients and compared its utility to the FRS for CVD risk assessment in RA patients.

 

Methods: A cross-sectional study of our RA cohort at a University Hospital. We included RA patients aged ≥40 years who met 1987 ACR criteria for RA, had a DXA and VFA scan available for analysis and access to their medical records to ascertain their CVD risk factors and details. The study was approved by our local I.R.B. Two blinded consultant musculoskeletal radiologists independently reviewed all VFA scans to determine AAC using an established 24-point scale. We determined if AAC was independently associated with prevalent CVD using multivariable logistic regression. The ability of the FRS and AAC for determining the presence of CVD was assessed using ROC curve analyses.

 

Results: 1330 patients were screened. 603 met the inclusion criteria: mean age 56 years, 74% female, 76% sero-positive and 43% smokers. 230 had ≥1documented CVD event. Overall AAC was present in 211 of subjects: 11% was mild(<9 points), 57% moderate(9-16) and 32% severe(>16 points). The proportion of patients with AAC was substantially greater in subjects with CVD than those without(76% Vs 10%, p <0.05). VFA-detected AAC was significantly better than traditional risk factors for determining the presence of CVD. In multivariable analyses both the presence and severity of AAC was significantly and independently associated with prevalent CVD (OR 2.70; 95% CI 1.8 to 3.2). Both the FRS (AUC 0.58) and AAC (AUC 0.85) were significant predictors of CVD events (Fig. 1). The addition of VFA-detected AAC to the FRS significantly enhanced the performance of the FRS for determining CVD (AUCs increased from 0.58 to 0.79, p<0.001).

 

Conclusion: VFA-detected AAC is an important marker of CVD risk in RA patients, and out-performs traditional risk prediction tools. Further studies are needed to examine the utility of DXA-detected AAC in CVD assessment in RA patients.

 

Fig 1: Additive Effect of AAC on FRS for Predicting CVD in RA Patients*

 

 


Disclosure:

A. Mohammad,
None;

D. Lohan,
None;

D. Bergin,
None;

S. Mooney,
None;

J. Newell,
None;

M. O’Donnell,
None;

R. J. Coughlan,
None;

J. J. Carey,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vertebral-fracture-assessment-detected-abdominal-aortic-calcification-enhances-cardiovascular-disease-risk-stratification-of-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology